SEC Comment Letter 0000000000-25-003800 to Royalty Pharma plc (RPRX)
Royalty Pharma plc
Date: April 9, 2025 · CIK: 0001802768 · Accession: 0000000000-25-003800
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 001-39329
Letter
Re: Royalty Pharma plc Form 10-K for the year ended December 31, 2024 Filed February 12, 2025 File No. 001-39329 Dear Terrance Coyne:
April 9, 2025
Terrance Coyne Chief Financial Officer Royalty Pharma plc 110 East 59th Street New York, NY 10022
We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation
Finance
Office of Life Sciences
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> April 9, 2025 Terrance Coyne Chief Financial Officer Royalty Pharma plc 110 East 59th Street New York, NY 10022 Re: Royalty Pharma plc Form 10-K for the year ended December 31, 2024 Filed February 12, 2025 File No. 001-39329 Dear Terrance Coyne: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences </TEXT> </DOCUMENT>